ECCO 2019: Drug survival for biologics differed significantly in Crohn’s disease
In this Norwegian study Bjoern Moum and colleagues aimed to investigate the drug survival of biologics in a national cohort of patients with Crohn’s disease. Data were collected from the Norwegian Patient Registry (NPR) and the Norwegian Prescription Database.
In total, 2444 CD patients were included in the study. After 3 years, the survival rate of first-line biologics for CD patients was 50.3% for infliximab and 40.5% for adalimumab (p < 0.001). For second-line treatment, the survival rates were 42.4% for infliximab, 42.8% for adalimumab and 69.8% for vedolizumab. Vedolizumab survival was significantly different compared with adalimumab and infliximab (p < 0.001).
Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.